Graham Meta-Analysis Ultimately Positive For Celebrex, Bextra

FDA Office of Drug Safety Associate Director for Science & Medicine David Graham's controversial presentation of unpublished studies on the safety of COX-2 inhibitors ultimately benefited certain COX-2s and raised questions about others in the class during a joint FDA advisory committee review